Barbour, Sean J
196  results:
Search for persons X
?
2

#812 Phase 2b ORIGIN study open label extension with atacic..:

Lafayette, Richard ; Maes, Bart ; Israni, Rubeen...
Nephrology Dialysis Transplantation.  39 (2024)  Supplement_1 - p. , 2024
 
?
4

#123 Impact of atacicept on hematuria in IGA nephropathy: p..:

Floege, Jürgen ; Barratt, Jonathan ; Maes, Bart...
Nephrology Dialysis Transplantation.  39 (2024)  Supplement_1 - p. , 2024
 
?
 
?
6

#425 Felzartamab (anti-CD38) in patients with IgA Nephropat..:

Floege, Jürgen ; Lafayette, Richard ; Barratt, Jonathan...
Nephrology Dialysis Transplantation.  39 (2024)  Supplement_1 - p. , 2024
 
?
7

#388 IONIS-FB-LRx, an antisense oligonucleotide to compleme..:

Hladunewich, Michelle ; Barbour, Sean ; Makris, Angela...
Nephrology Dialysis Transplantation.  39 (2024)  Supplement_1 - p. , 2024
 
?
9

Phase 2 Trial of Cemdisiran in Adult Patients with IgA Neph..:

Barratt, Jonathan ; Liew, Adrian ; Yeo, See Cheng...
Clinical Journal of the American Society of Nephrology.  19 (2024)  4 - p. 452-462 , 2024
 
?
 
?
11

#3848 ORIGIN TRIAL: 24-WK PRIMARY ANALYSIS OF A RANDOMIZED,..:

Lafayette, Richard ; Maes, Bart ; Lin, Celia...
Nephrology Dialysis Transplantation.  38 (2023)  Supplement_1 - p. , 2023
 
?
12

PROTECTing the kidneys in IgA nephropathy:

Reich, Heather N ; Barbour, Sean J
The Lancet.  402 (2023)  10417 - p. 2046-2047 , 2023
 
?
15

Are patients with primary glomerular disease at increased r..:

Han, Jialin ; Zhao, Yinshan ; Canney, Mark...
Nephrology Dialysis Transplantation.  39 (2023)  6 - p. 910-919 , 2023
 
1-15